A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.

The invention relates to a product dispensing device configured to cooperate with a product reservoir that has product dispensing means, having a dispensing duct which is configured to dispense a product from the product dispensing means into the mouth of a user in a manner that is sealed against outside air, trigger means that trigger the dispensing of the product when the air pressure (Ai) in the dispensing duct is a predefined value greater than the pressure of the outside air (A). The invention further relates to a product administration kit having such a product dispensing device and to a product administration unit having such a product dispensing device.

An acoustic dose meter is provided comprising a housing, and a cylindrical seat for staging a pressurized medicine canister. The housing includes at least one compartment for housing electronics and passageways for connecting electronics for power and data communication. A microprocessor including a transient memory containing machine instruction is also included. Additionally, a power source connected to the microprocessor, a power switch connected to the microprocessor and the power source for booting the microprocessor are added. At least one visual display device connected to the microprocessor for displaying available doses is provided. A first set of acoustic sensors connected to the microprocessor and adapted as acoustic sound generators and a second set of acoustic sensors connected to the microprocessor and adapted as acoustic soundwave recorders are implemented to detect and analyze frequencies enabling determining of dosing count availability.

A handheld misting device has a housing having a dispensing window is arranged and configured to contain a sonic generator, a power source coupled to the sonic generator, a plurality of reservoirs, each containing a liquid, and a plurality of nozzles, each nozzle arranged and configured for removable coupling to the sonic generator. Each nozzle is associated with and in liquid communication with a single reservoir. The sonic generator includes a converter and an elongate horn having a proximal end coupled to the converter and a distal end, and the nozzle is removably coupled to the distal end of the horn. Thus, the device delivers the liquid through a delivery opening formed in the nozzle, and activating the sonic generator energizes the liquid in the nozzle to generate an aerosol plume that is delivered through the dispensing window.

Methods and systems for monitoring the status and usage of a metered dose inhaler (MDI) and communicating status, usage, and guidance information to a user of the MDI and to a mobile computing device are presented herein. An IMD includes a dosage dispense detection device, an accelerometer, and a visual transducer, an audio transducer, a haptic transducer, or any combination thereof. The dosage dispense detection device detects when a user applies a compressive force across the IMD. The accelerometer measures a shaking of the IMD by a user before self-administering a dose. The IMD determines whether the medicine is adequately shaken by the user, and if so, communicates an indication to the user that the pressurized canister of medicine is ready for dosage. In another aspect, the IMD communicates a sequence of indications that mark each transition of a dosage regimen plan to self-administer a dosage of medicine.

An aerosol-generating system (includes a cartridge, a liquid aerosol-forming substrate, and an aerosol-generating device. The cartridge includes a cartridge housing and a solid aerosol-forming substrate. The aerosol-generating device includes a cavity configured to receive at least a portion of the cartridge, an airflow inlet, and an airflow sensor. The airflow sensor is in fluid communication with the airflow inlet and the cavity). The aerosol-generating device includes a bypass air inlet in fluid communication with the cavity, an electric heater configured to heat the liquid aerosol-forming substrate, a power supply, and a controller. The aerosol-generating system is configured so that the cartridge housing substantially prevents airflow through the bypass air inlet when the cartridge is received within the cavity.

An inhaler for facilitating inhalation of dry powder includes a body defining an interior space and a mouth piece. At least one annular member is positioned within the interior space and is rotatable with respect to the mouth piece. The at least one annular member includes a plurality of compartments. Each compartment defines a cavity configured to hold dry powder. Each compartment includes at least one flap and an opening configured to release the dry powder when the at least one flap is reconfigured from a closed position to an open position. The at least one flap covers the opening and inhibits the dry powder from being released from the cavity in the closed position.

The present disclosure is directed to an aerosol delivery device and a holder for use with a removable substrate cartridge. In one implementation, the holder includes a first body portion and a second body portion, the first body portion defining a main body and a guide post that defines a receiving chamber extending at least a portion therethrough. The second body portion is configured to rotate about and slide along at least a portion of the guide post to and from a use position, wherein the second body portion is proximate the main body of the first body portion and the substrate cartridge is retained in the receiving chamber, and an open position, wherein the second body portion is rotated relative to and extended away from the main body of the first body portion such that the substrate cartridge can be inserted into or removed from the receiving chamber.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.